Biosimilars Access Assessment

“Biosimilars” are biologic medicines approved by the FDA as “highly similar” to the original biologic medicine such that they work in the same way and have no clinically meaningful difference in safety or efficacy. Biosimilars increase treatment options in critical disease areas and have the potential to lower health care costs for patients, states (and taxpayers), and insurers. However, the potential of these savings has not yet been realized, and it's important to understand any access barriers that may be contributing factors, and if there are policy solutions that can be explored for greater use and, therefore, savings.

Question Title

* 1. What is your area of medical specialty?

Question Title

* 2. How long have you been practicing?

1-5 years

6-10 years

11-15 years

16+ years

Question Title

* 3. How knowledgeable are you regarding biosimilars?

I am not familiar with biosimilars

I know what biosimilars are

I have patients under my care treated with biosimilars

I have prescribed biosimilar treatments for my patients

Question Title

* 4. Are there biosimilar treatment options on the market for patients you treat?

Yes

Uncertain

Question Title

* 5. Have you wanted to prescribe a biosimilar but had trouble with the patient accessing that treatment?

Yes

Not Applicable

Uncertain

Question Title

* 6. What are the access barriers you have faced when wanting to prescribe a biosimilar?

Formulary restriction

Higher out of pocket cost to the patient vs the original reference biologic

Need to step through reference biologic before gaining access to the biosimilar

Not Applicable

Other (please specify)

Question Title

* 7. How confident would you be prescribing biosimilars to your patients?

Extremely confident

Very confident

Somewhat confident

Not at all confident

I'm not familiar enough with biosimilars to respond

Question Title

* 8. Would you be interested in learning more about biosimilars, the savings they offer, and policy solutions to overcome barriers?

Yes